Upgrade to SI Premium - Free Trial

ResMed (RMD) PT Lowered to $300 at UBS

July 21, 2026 8:57 AM
UBS analyst David Low lowered the price target on ResMed (NYSE: RMD) to $300.00 (from $312.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change